Circio Holding ASA Company Description

Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines.

The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells.

It has a collaboration with Certest Biotec, S.L. for formulation of circVec into lipid nanoparticles.

The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023.

The company was incorporated in 2010 and is based in Oslo, Norway.

Circio Holding ASA

Country	Norway
Founded	2010
Industry	Biotechnology
Sector	Healthcare
Employees	9
CEO	Erik Wiklund

Contact Details

Address: St. Olavs Plass 5 Oslo, 0165 Norway
Phone	47 92 95 17 88
Website	circio.com

Stock Details

Ticker Symbol	CRNA
Exchange	Oslo Børs
Fiscal Year	January - December
Reporting Currency	NOK
ISIN Number	NO0013033795
SIC Code	2836

Key Executives

Name	Position
Dr. Erik Digman Wiklund	Chief Executive Officer
Dr. Lubor Gaal Ph.D.	Chief Financial Officer and Head of BD
Ola Melin	Chief Operating Officer
Dr. Thomas Birkballe Hansen	Chief Technology Officer
Dr. Victor Levitsky M.D., Ph.D.	Chief Scientific Officer
Jon Amund Eriksen M.Sc., MSc	Special Advisor
Prof. Gustav Gaudernack Ph.D.	Chief Scientific Adviser
Dr. Peter Skorpil Ph.D.	Vice President of Business Development